MapLight Therapeutics Files 8-K on Phase 2 ZEPHYR Trial Results

AI-generated NewsSnap summary based on source reporting.
Published: 2026-07-27
Category: business
Source: SEC.gov
Original source

MapLight Therapeutics, Inc. filed a Form 8-K to announce an upcoming conference call to discuss topline results from its Phase 2 ZEPHYR trial. The trial evaluated ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis. This filing indicates the imminent disclosure of significant clinical study data.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai